Industry Overview - The MedSurg equipment market is projected to grow at a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 [1] - The growth is driven by an aging population, rising chronic diseases, and rapid technological advancements [3] Boston Scientific (BSX) - Boston Scientific's MedSurg segment is gaining market share, particularly in Endoscopy, Urology, and Neuromodulation [4] - The Endoscopy segment is experiencing growth due to endoluminal surgery and single-use imaging [4] - Urology is benefiting from strong contributions from the Core Stone and prosthetic urology franchises [4] - Neuromodulation is boosted by new products like Cartesia leads and Lumina 3D programming algorithm [4] - The structural heart segment is also performing well, with a 24% growth in WATCHMAN sales [5] - Emerging markets are a vital growth engine, with net sales growing nearly 9.8% year-over-year [6] - In Q1, Boston Scientific reported an adjusted gross margin increase of 19 basis points and an operating margin improvement of 127 basis points [7] - The company raised its full-year 2025 outlook, projecting 15-17% reported net sales growth and adjusted EPS of $2.87-$2.94 [7] Medtronic (MDT) - Medtronic's MedSurg portfolio is benefiting from positive sales momentum in Surgical Robotics, particularly the Hugo robotic-assisted surgery system [8] - The Hugo RAS system has expanded its installed base to 30 countries, with growth in procedure volumes and utilization [8] - Medtronic is seeing significant growth in Cardiac Ablation Solutions, with nearly 30% growth in the fiscal fourth quarter [9] - The company is focused on expansion in emerging markets, which grew mid-single digits in the quarter [11] - Medtronic's operational performance in Q1 showed gross margin improvement of 19 basis points and operating margin growth of 210 basis points [12] - For fiscal 2026, Medtronic projects organic revenue growth of 5% over fiscal 2025 [12] Stock Performance - Over the past year, Boston Scientific's shares have risen by 35.2%, while Medtronic's shares have gained only 7.4% [13] - Boston Scientific is trading at a forward five-year price-to-sales (P/S) ratio of 7.5X, compared to Medtronic's 3.1X [15] - The Zacks Consensus Estimate for Boston Scientific's 2025 EPS implies a year-over-year improvement of 15.9% [17] - Analysts have shown declining confidence in Medtronic, with downward EPS estimate revisions in the last 60 days [18] Investment Outlook - Boston Scientific is gaining strength across MedSurg and structural heart segments, supported by innovation and global expansion [19] - Despite expected tariff impacts, Boston Scientific's raised guidance reflects confidence in sustained growth [19] - Medtronic, while carrying a Zacks Rank 4 (Sell), may attract value-focused investors due to its discounted P/S ratio [20]

Core Viewpoint - The recent ruling by an Administrative Law Judge establishes that the ReWalk Exoskeleton is a "reasonable and necessary" medical device for enabling paralyzed individuals to walk, paving the way for Medicare coverage and potentially broader commercial insurance access [1][2]. Group 1: Legal and Regulatory Developments - The ALJ ruling supports an appeal by a Medicare beneficiary for coverage of the ReWalk Exoskeleton, affirming its medical necessity for individuals with spinal cord injuries [1]. - This ruling builds on a prior decision by the Centers for Medicare & Medicaid Services (CMS) in April 2024, which finalized a reimbursement pathway for personal exoskeletons [2]. Group 2: Company Innovations and Products - The ReWalk Exoskeleton is noted as the only personal exoskeleton that allows paralyzed individuals to navigate stairs and curbs, in addition to walking in everyday environments [2]. - The latest model, ReWalk 7, received FDA clearance in March 2025 and is now commercially available in the United States [2]. Group 3: Company Mission and Vision - Lifeward aims to transform the lives of individuals with physical limitations through innovative medical technology, focusing on expanding data and programs for the paralyzed community [2][3]. - The company is committed to delivering groundbreaking solutions that empower individuals to regain mobility and improve their quality of life [3].

Core Viewpoint - InMode Ltd. reported a decline in revenues and net income for Q1 2025 compared to Q1 2024, attributed to a challenging macroeconomic environment and weakened consumer demand, while maintaining a strong focus on innovation and capital allocation strategies [4][10]. Financial Performance - Total GAAP revenues for Q1 2025 were $77.9 million, a decrease of 3% from $80.3 million in Q1 2024 [8]. - GAAP net income for Q1 2025 was $18.2 million, or $0.26 per diluted share, down from $23.7 million, or $0.28 per diluted share in Q1 2024 [10]. - Non-GAAP net income for Q1 2025 was $21.4 million, or $0.31 per diluted share, compared to $27.7 million, or $0.32 per diluted share in Q1 2024 [10]. Margins and Expenses - GAAP gross margin for Q1 2025 was 78%, down from 80% in Q1 2024, while non-GAAP gross margin was 79%, also down from 80% [8]. - GAAP operating margin decreased to 20% in Q1 2025 from 23% in Q1 2024, with non-GAAP operating margin dropping to 23% from 27% [9]. Shareholder Returns - The company completed a share repurchase program of 6.95 million shares for a total of $127 million, returning over $412 million to shareholders in the past 12 months, representing approximately 27% of its share capital [5][6]. Cash Position - As of March 31, 2025, InMode had a total cash position of $512.9 million, including cash and cash equivalents, marketable securities, and short-term bank deposits [11]. International Performance - InMode achieved record revenue in Europe during Q1 2025, despite ongoing market headwinds, indicating strong international performance [4]. Future Outlook - Management anticipates continued challenges in the U.S. market, projecting a 4%-5% decline in operating margins and an expected impact of 2%-3% on gross margins due to U.S. tariffs [7]. - The company has revised its 2025 financial outlook, expecting revenues between $395 million and $405 million, with non-GAAP gross margins between 78% and 80% [16].

As filed with the Securities and Exchange Commission on January 18, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________ Envoy Medical, Inc. (Exact name of registrant as specified in its charter) _____________________ | Delaware | 3842 | 86-1369123 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (IRS Employer | | incorporation or organi ...